GlassScriptPhysician profile
Jayprakash D Patel
NPI 1083699334
$3,213.98
in general payments reported to CMS, 2019-2025
22 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.48 · 2020: $374 · 2021: $433 · 2022: $862 · 2023: $669 · 2024: $391 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.43 | 2020-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $375.54 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $282.54 | 2019-2023 | Xarelto |
| Abbott Laboratories | $272.78 | 2022-2025 | Mitraclip, Freestyle Libre 3 |
| Novo Nordisk INC | $222.56 | 2022 | |
| Abbvie INC. | $203.79 | 2021-2025 | |
| Pfizer INC. | $178.63 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $175.46 | 2022-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $153.20 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $142.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $128.69 | 2022-2025 | Otezla, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $108.60 | 2024-2025 | Orgovyx, Gemtesa |
| Esperion Therapeutics, INC. | $89.19 | 2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $88.06 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $74.40 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $60.07 | 2019-2023 | Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.81 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $21.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.08 | 2022 | |
| Amarin Pharma, INC. | $15.56 | 2021 | |
| Allergan, INC. | $14.76 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.52 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayprakash Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.